These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 6429387)

  • 1. [Effects of FOY on lysosomes in hemorrhagic hypotension--a histological analysis].
    Miyawaki T; Sameshima T; Miyao J; Oda T
    Masui; 1984 Mar; 33(3):263-8. PubMed ID: 6429387
    [No Abstract]   [Full Text] [Related]  

  • 2. Antishock effect of gabexate mesilate (FOY).
    Oda T; Miyawaki T; Sameshima T; Miyao J; Arai Y; Yoshimine K; Yoshimura N
    Prog Clin Biol Res; 1983; 111():293-307. PubMed ID: 6408649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-carcinogenic effects of a serine protease inhibitor (FOY-305) through the suppression of neutral serine protease activity during chemical hepatocarcinogenesis in rats.
    Yamauchi Y; Kobayashi M; Watanabe A
    Hiroshima J Med Sci; 1987 Mar; 36(1):81-7. PubMed ID: 2884198
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of the serine protease inhibitors FOY and FOY 305 on phospholipase A1 (EC 3.1.1.32) activity in rat - liver lysosomes.
    Kunze H; Bohn E
    Pharmacol Res Commun; 1983 May; 15(5):451-9. PubMed ID: 6412250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The lysosomal stabilizing effects of some antishock agents].
    Miyawaki T; Oda T; Sameshima T; Miyao J
    Masui; 1988 Jul; 37(7):815-22. PubMed ID: 2466132
    [No Abstract]   [Full Text] [Related]  

  • 6. Influence of a small molecular weight proteinase inhibitor, gabexate mesilate (FOY), on insulin receptor function in vitro.
    Göke R; Göke B; Steinfelder HJ; Arnold R
    Int J Pancreatol; 1988 Mar; 3(2-3):135-42. PubMed ID: 3129526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human adult mesenchymal stem cells improve rat spatial cognitive function after systemic hemorrhagic shock.
    Plaschke K
    Behav Brain Res; 2009 Aug; 201(2):332-7. PubMed ID: 19428653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Inhibitory effect of FOY-305 on liver metastasis of the pancreatic cancer].
    Ohta T; Futagami F; Arakawa H; Tsukioka Y; Kitagawa H; Kayahara M; Nagakawa T; Miyazaki I
    Gan To Kagaku Ryoho; 1996 Oct; 23(12):1669-72. PubMed ID: 8886041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FOY: [ethyl p-(6-guanidinohexanoyloxy) benzoate] methanesulfonate as a serine proteinase inhibitor. II. In vivo effect on coagulofibrinolytic system in comparison with heparin or aprotinin.
    Ohno H; Kambayashi J; Chang SW; Kosaki G
    Thromb Res; 1981 Dec 1-15; 24(5-6):445-52. PubMed ID: 6178174
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of the synthetic protease inhibitor [N,N-dimethylcarbamoyl-methyl 4-(4-guanidinobenzoyloxy)-phenylacetate] methanesulfate on carcinogenesis by 3-methylcholanthrene in mouse skin.
    Ohkoshi M; Fujii S
    J Natl Cancer Inst; 1983 Nov; 71(5):1053-7. PubMed ID: 6580482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recovery from a usually lethal period of hypotension. Structural alterations in surviving dogs.
    Henson EC; Lockard VG; Crowell JW; Arhelger RB; Brunson JG
    Arch Pathol; 1973 Feb; 95(2):73-6. PubMed ID: 4683163
    [No Abstract]   [Full Text] [Related]  

  • 12. Cellular (thrombocytes, granulocytes) effects of proteinase inhibitors--gabexylate, gabexate mesilate (FOY) and aprotinin.
    Redl H; Schlag G; Paul E; Schiesser A
    Resuscitation; 1986 Sep; 14(1-2):81-90. PubMed ID: 2431445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The effects of protease inhibitors on glioma cells in culture].
    Obonai C
    Nihon Gan Chiryo Gakkai Shi; 1988 Aug; 23(8):1720-6. PubMed ID: 2461424
    [No Abstract]   [Full Text] [Related]  

  • 14. [Protease inhibitors as anticancer chemotherapy--experimental and clinical studies].
    Ohkoshi M
    Gan To Kagaku Ryoho; 1995 Mar; 22(4):417-30. PubMed ID: 7887633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endotoxins and coagulation parameters in patients with traumatic haemorrhagic- and bacteriotoxic shock.
    Stemberger A; Strasser F; Blümel G; von Hundelshausen B; Jelen S; Schmidt O; Tempel G
    Adv Exp Med Biol; 1984; 167():439-48. PubMed ID: 6201049
    [No Abstract]   [Full Text] [Related]  

  • 16. [Disorders of cardiac contractility caused by hemorrhagic hypotension].
    Toropov AP; Dolgikh VT
    Anesteziol Reanimatol; 2000; (2):40-4. PubMed ID: 10833836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of serine protease inhibitor FOY-305 and heparin on the growth of squamous cell carcinoma.
    Ohkoshi M; Akagawa T; Nakajima M
    Anticancer Res; 1993; 13(4):963-6. PubMed ID: 8352567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes of serum amino acid concentrations in experimentally induced endotoxic shock. The significance of hyperalaninemia in the prediction of lethality.
    Metzler B; Rettenmeier AW; Wodarz I; Schmahl FW
    Prog Clin Biol Res; 1989; 308():595-9. PubMed ID: 2506574
    [No Abstract]   [Full Text] [Related]  

  • 19. [Inhibition of platelet aggregation and prevention of endotoxin-induced DIC by a protease inhibitor, FUT-175, in rats].
    Yoshikawa T; Murakami M; Furukawa Y; Onodera H; Yoshida N; Ueda M; Kato H; Takemura S; Sugino S; Kondo M
    Masui; 1984 Apr; 33(4):397-402. PubMed ID: 6471360
    [No Abstract]   [Full Text] [Related]  

  • 20. Elimination of the low-molecular weight proteinase inhibitor camostate (FOY 305) and its degradation products by the rat liver.
    Beckh K; Göke B; Müller R; Arnold R
    Res Exp Med (Berl); 1987; 187(6):401-6. PubMed ID: 3441682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.